Targeting mutant p53 for efficient cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The TP53 gene, a critical tumor suppressor, is frequently mutated in various cancers.
• Mutations in TP53 lead to the inactivation of p53 protein, promoting tumor cell survival and progression.
• Restoring wild-type p53 function is a key therapeutic strategy for cancer treatment.

Purpose of the Study:

• To review recent advancements in the pharmacological reactivation of mutant p53.
• To discuss novel strategies targeting both missense and nonsense TP53 mutations.
• To highlight the challenges and potential of p53-targeted cancer therapies.

Main Methods:

• Identification of small molecules capable of reactivating missense-mutant p53.
• Development of novel therapeutic approaches for TP53 nonsense mutations.
• Clinical trials evaluating the efficacy of p53-restoring compounds.

Main Results:

• Several small molecules have been identified that can restore the function of missense-mutant p53.
• Two compounds targeting missense mutations are currently undergoing clinical trials.
• Emerging strategies are being developed to address TP53 nonsense mutations.

Conclusions:

• Pharmacological reactivation of mutant p53 holds significant promise for cancer therapy.
• Targeting TP53 mutations offers a potential pathway to trigger tumor cell death and elimination.
• Further research and clinical evaluation are essential to realize the full therapeutic potential of these strategies.